Valneva SE ADR

Yahoo Finance • 3 days ago

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®

Long-lasting antibody persistence was comparable in older (65+) and younger adults Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya Saint-Herblain (Fran... Full story

Yahoo Finance • 3 days ago

Valneva annonce un taux de séroréponse de 95% quatre ans après une vaccination avec une seule dose du vaccin contre le chikungunya IXCHIQ®

Persistance des anticorps chez les adultes âgés de 65 ans et plus, comparable à celle des jeunes adultes La durabilité de la réponse immunitaire est un avantage compétitif clé pour un vaccin ciblant une maladie épidémique comme le chikungu... Full story

Yahoo Finance • 8 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN).  Such investors are advised to contact Danielle Peyton at newaction@pom... Full story

Yahoo Finance • 14 days ago

VALNEVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Valneva SE on Behalf of Valneva Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Valneva (VALN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Valneva and would like to disc... Full story

Yahoo Finance • 30 days ago

Valneva's VLA15 Lyme Vaccine Shows Strong Booster Response In Phase 2 Trial

(RTTNews) - Valneva SE(VALN, VLA.PA) announced positive immunogenicity and safety results from its ongoing Phase 2 clinical trial of the Lyme disease vaccine candidate, VLA15. The data show a strong anamnestic immune response and a favorab... Full story

Yahoo Finance • 30 days ago

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate

Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypesNo safety concerns observed in any age group by independent Data Monitoring Committee (DMC), co... Full story

Yahoo Finance • 30 days ago

Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme

Forte réponse immunitaire chez les enfants et les adultes après la troisième vaccination annuelle de rappelForte réponse anamnestique observée pour les six sérotypes Aucun problème de sécurité observé dans toutes les tranches d’âge par le... Full story

Yahoo Finance • last month

Johnson Fistel Investigates Valneva Following FDA Suspension

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Valneva SE (NASDAQ: VALN) regarding possible violations of federal securities laws. Investors... Full story

Yahoo Finance • last month

Biggest stock movers Monday: NIO, VALN, and more

[Woman trading stock with mobile app in front of stock exchange screen.] Guido Mieth Stock futures edged lower Monday morning as Wall Street kicked off the final trading week of August with focus on Nvidia’s upcoming earnings. Here are s... Full story

Yahoo Finance • 2 months ago

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the pr... Full story

Yahoo Finance • 2 months ago

Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus

Saint-Herblain (France), le 18 août 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que Santé Canada a accordé une autorisation de mise sur le marché pour son vaccin à d... Full story

Yahoo Finance • 2 months ago

Valneva reports 1H results; reaffirms FY outlook

* Valneva press release [https://seekingalpha.com/pr/20196941-valneva-reports-half-year-2025-financial-results-and-provides-corporate-updates] (NASDAQ:VALN [https://seekingalpha.com/symbol/VALN]): 1H net loss of €20.8 million compared to... Full story

Yahoo Finance • 2 months ago

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates

Total revenues of €97.6 million compared to €70.8 million in the first half of 2024Cash and cash equivalents of €161.3 million at end of June 2025Further clinical and regulatory progress2025 financial outlook confirmed Saint-Herblain (Fra... Full story

Yahoo Finance • 2 months ago

Valneva publie ses résultats financiers du premier semestre 2025 et fait un point sur ses activités

Chiffre d’affaires de 97,6 millions d’euros contre 70,8 millions d’euros au premier semestre 2024Trésorerie de 161,3 millions d’euros à fin juin 2025Poursuite des avancées cliniques et réglementaires Confirmation des perspectives 2025 Sai... Full story

Yahoo Finance • 2 months ago

FDA lifts pause on Valneva's chikungunya vaccine in elderly

[Medical form with diagnosis Chikungunya in a hospital.] designer491/iStock via Getty Images Valneva SE (NASDAQ:VALN [https://seekingalpha.com/symbol/VALN]) said on Thursday that the FDA has lifted its pause on the use of its chikungunya... Full story

Yahoo Finance • 2 months ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information

Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ® in individuals 60 years of age and... Full story

Yahoo Finance • 2 months ago

Valneva annonce la levée de l’arrêt temporaire de la FDA sur l’utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées et une mise à jour des caractéristiques du produit

Saint Herblain (France), le 7 août 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui la levée de l’arrêt temporaire de l’agence de santé américaine Food and Drug Administrati... Full story

Yahoo Finance • 3 months ago

CSL to replace Bavarian Nordic in Valneva’s vaccine deal for Germany

[Tip of fountain pen writing] Martin Barraud * French biotech Valneva SE (NASDAQ:VALN [https://seekingalpha.com/symbol/VALN]) announced Thursday a partnership with Australian company CSL Limited (OTCQX:CSLLY [https://seekingalpha.com/sy... Full story

Yahoo Finance • 3 months ago

Valneva Selects CliniOps as the Technology Partner for Multiple Post-Marketing Studies to Support the IXCHIQ Chikungunya Vaccination Program in Brazil

This collaboration underscores CliniOps’ continued mission to transform clinical research through smart technologies, enabling equitable access, operational efficiency, and robust data quality, even in hard-to-reach geographies. FREMONT,... Full story

Yahoo Finance • 6 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN).  Such investors are advised to contact Danielle Peyton at newaction@pom... Full story